Novartis - Featured news

Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria.

Thu, 25 Apr 2013 16:45:00 +0100

Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria.

Novartis Pharmaceuticals Corporation recognized among the best employers for diversity in the US by DiversityInc.

Thu, 25 Apr 2013 16:40:00 +0100

Novartis discloses compensation for new Chairman and Chairman ad-interim.

Wed, 24 Apr 2013 07:40:00 +0100

Novartis announced today the compensation for the incoming Chairman of the Board, starting August 1, 2013, as well as the pro-rated compensation for the current Chairman ad-interim. This new disclosure ahead of the 2013 Annual Report reflects the commitment to greater transparency by the Board of Directors and the company.

Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth.

Wed, 24 Apr 2013 07:30:00 +0100

Complex realities of global healthcare.

Tue, 19 Mar 2013 10:35:00 +0100

Watch this trailer that pulls from all six films to introduce you to six children from around the world each facing a complex reality of healthcare.

Yoseline, a young, vivacious girl receiving cancer treatment in the United States.

Tue, 19 Mar 2013 10:30:00 +0100

This video is one in a series produced by filmmaker Martin Bell to accompany photography by Mary Ellen Mark as part of the Novartis Annual Report 2012. Novartis commissioned this series which is meant to capture the diverse experiences of children in various settings, demonstrating the complex realities of global healthcare.

Novartis Foundation for Sustainable Development annual report is now available.

Thu, 07 Mar 2013 10:30:00 +0100

New Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa.

Thu, 07 Mar 2013 10:35:00 +0100

Basel, Switzerland/Cambridge, MA, February 28, 2013 - Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka University Teaching Hospital (UTH), the Ministry of Health in Zambia, the Pan-African Cardiology Society and Massachusetts General Hospital (MGH).

Fortune's World's Most Admired Companies 2013.

Thu, 28 Feb 2013 18:30:00 +0100

Novartis ranked top pharmaceutical company in Fortune's World's Most Admired Companies 2013

Novartis recognized by MIT Technology Review as one of the world's most innovative companies.

Fri, 22 Feb 2013 16:30:00 +0100

Novartis recognized by MIT Technology Review in its annual 50 Disruptive Companies list as one of the world's most innovative companies.

MedAdNews – Novartis recognized as having the "Most Innovative Pipeline" for the third consecutive year.

Fri, 01 Feb 2013 15:30:00 +0100

This annual special feature identifies and profiles 10 therapeutic pipeline categories covering pharma, biopharmaceutical and biotech companies as chosen by Med Ad News editors.

Novartis CEO Joseph Jimenez talks about learning from failure.

Tue, 29 Jan 2013 12:30:00 +0100

What do you tell a team that has failed?

Novartis announced the One Million Community Health Worker Campaign.

Thu, 24 Jan 2013 15:30:00 +0100

The campaign is a Solutions Initiative of the United Nations Sustainable Development Solutions Network.

Novartis CEO Joseph Jimenez announces fourth quarter and full year 2012 results.

Wed, 23 Jan 2013 07:30:00 +0100

Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013.

Wed, 23 Jan 2013 07:00:00 +0100

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year

Novartis CEO Joe Jimenez discusses how sustainable health systems in developing countries could have a lasting impact on worldwide health.

Wed, 23 Jan 2013 06:30:00 +0100

BASEL – When it comes to health care, all stakeholders – patients, service providers, pharmaceutical companies, and governments – know that something needs to change.

Novartis makes progress in the fight to eliminate leprosy worldwide.

Thu, 17 Jan 2013 17:30:00 +0100

Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs).

Students in our 2012 Next Generation Scientist program describe their experiences.

Mon, 14 Jan 2013 08:00:00 +0100

"Being in the Next Generation Scientist program is the best thing that could happen to you. It will change the way you do research and how you communicate your research. It's awesome."

Novartis CEO Joe Jimenez: The best advice I ever got

Thu, 10 Jan 2013 09:00:00 +0100

What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valuable feedback and how he used this advice to turn an unexpected career move into a learning experience.

Highlights from the 2012 symposium in the Novartis Foundation for Sustainable Development's latest newsletter

Thu, 20 Dec 2012 08:00:00 +0100

The annual symposium, held on December 4, gathered experts from four continents in Basel to discuss experiences and perspectives related to psychosocial support for Africa's children.

Novartis Foundation symposium 2012: speakers discuss psychosocial support for children in sub-Saharan Africa

Tue, 4 Dec 2012 08:00:00 +0100

Event gives actors in the field the opportunity to assess psychosocial approaches and discuss various interventions that strive to ensure mental health and wellbeing for Africa's children.

Novartis awarded two of the prestigious SCRIP Awards for excellence in innovation and R&D

Thu, 29 Nov 2012 17:00:00 +0100

Novartis has been awarded two of the prestigious SCRIP Awards for excellence in innovation and research and development (R&D). The annual awards event celebrates industry achievements in a number of categories and are considered the premier awards for the global biopharmaceuticals industry.

Novartis CEO Jimenez: Three ideas on how to combat chronic disease in an aging population – prevention, innovation, technology.

Mon, 26 Nov 2012 17:00:00 +0100

What will the future of health and healthcare look like? In a joint series of blog posts by the World Economic Forum's Strategic Foresight and Health teams, a number of leading voices will present their own visions for the future. Contributions are linked to the Scenarios for Sustainable Health Systems project, the Workplace Wellness Alliance and the Healthy Living Initiative. In the following post, Joseph Jimenez, Chief Executive Officer of Novartis, will share his perspective on the future of health.

Novartis announces update to company's Board of Directors to take effect in February 2013

Fri, 09 Nov 2012 10:00:00 +0100

Basel, November 9, 2012 - Novartis announced today that Marjorie Yang has decided not to seek re-election to the Novartis Board of Directors at the Novartis Annual General Meeting in 2013. Ms. Yang joined the Novartis Board in 2007 and her current term is ending in 2013.

Novartis provides updates on its leading research and development (R&D) pipeline

Thu, 08 Nov 2012 20:00:00 +0100

Novartis R&D Day 2012 held on November 8th in Cambridge, MA, (USA) is an Investor event with senior Novartis executives discussing developments in research and development (R&D) across its divisions including Oncology and Pharmaceuticals.

Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million

Wed, 31 Oct 2012 10:00:00 +0100

Singapore, October 31, 2012 - Novartis announced today the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology. It will be co-located with the pharmaceutical production site based in Tuas, Singapore. In the future, Singapore is expected to be a technological competence center for both biotechnology and pharmaceutical manufacturing at Novartis.

1st Anniversary: Novartis proud part of WIPO Re:Search consortium, successfully accelerating research in neglected diseases

Tue, 30 Oct 2012 11:00:00 +0100

Novartis is a founding member of WIPO Re:Search, a consortium established to accelerate discovery and development of medicines, vaccines and diagnostics for neglected tropical diseases.

Newsweek 2012 Green Rankings

Tue, 30 Oct 2012 10:45:00 +0100

Novartis is the greenest healthcare company worldwide

Novartis announces its results for the third quarter of 2012 today

Thu, 25 Oct 2012 17:45:00 +0100

Read the latest updates on Novartis seasonal influenza vaccines on our dedicated website

Thu, 25 Oct 2012 12:45:00 +0100

Novartis confirms its confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal® and Fluad® manufactured in Italy. Patient safety is of the highest priority to Novartis.

Novartis confident in safety and efficacy of its seasonal influenza vaccines produced in Italy. Read the media release

Thu, 25 Oct 2012 12:30:00 +0100

Novartis confirms its confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal® and Fluad® manufactured in Italy. Patient safety is of the highest priority to Novartis.

Novartis Foundation for Sustainable Development's latest newsletter

Fri, 19 Oct 2012 10:30:00 +0100

Read about global development post 2015 in the Novartis Foundation for Sustainable Development's latest newsletter

Listen to physicians answering common questions about life with advanced breast cancer.

Mon, 08 Oct 2012 13:00:00 +0100

People around the world living with advanced breast cancer face many uncertainties and unanswered questions about their diagnosis. Listen as top physicians Dr. Mariana Chavez MacGregor, Dr. Jennifer Litton and Dr. Joyce O'Shaughnessy answer common questions about life with the disease and how it differs from the earlier stages of breast cancer.

"Count Us, Know Us, Join Us" is a program for patients with advanced breast cancer.

Wed, 03 Oct 2012 17:00:00 +0100

Episode 1 of the Each Voice Counts talk show series, "The Women: Part 1" features four women sharing their stories of life with advanced breast cancer. Each Voice Counts is part of the Count Us, Know Us, Join Us program, the mission of which is to recognize those living with advanced breast cancer, their caregivers, supporters, friends and family members. We invite you to join us in supporting this community to reinforce that they do count.

Novartis named "Most Admired Pharmaceutical Company 2012" for the 4th consecutive year

Thu, 27 Sep 2012 18:30:00 +0100

Novartis is the most admired pharma company for the fourth straight year; Biogen Idec and Shire are first-time winners in the biotech and specialty categories.

Science's 2012 Top Employer

Tue, 25 Sep 2012 13:30:00 +0100

Novartis brand ranks no. 39 globally and no. 2 in Switzerland

Eurobrand's Global Top 100 Brand Corporations

Tue, 25 Sep 2012 13:30:00 +0100

Novartis ranked no. 11 on Science's Top 20 Employers list

2012 Working Mother's 100 Best Companies

Tue, 25 Sep 2012 13:30:00 +0100

Novartis Pharma US named one of the best employers for working mothers.

Universum's World's Most Attractive Employers

Mon, 24 Sep 2012 17:30:00 +0100

Novartis named one of the top 50 most attractive employers worldwide for engineering students by Universum.

Corporate responsibility and philanthropy in the Novartis Foundation for Sustainable Development

Wed, 12 Sep 2012 17:30:00 +0100

The UN Millennium Development Goals (MDG) Report 2011 gives grounds for optimism: lives have been saved; poverty has declined; and child mortality has been reduced. Yet in spite of these poverty alleviation efforts over 2.5 billion people continue to live on USD 2 or less a day.

Novartis International BioCamp 2012

Fri, 31 Aug 2012 17:30:00 +0100

Novartis International BioCamp highlights global R&D reach to meet patient needs in emerging markets

Sandoz supports Zambian government in increasing access to high-quality, affordable medicines through Health Shops

Fri, 31 Aug 2012 17:30:00 +0100

On August 20, Sandoz and its subsidiary 1A Pharma announced its support for an innovative initiative by the Zambian government. Called Health Shops, this initiative will allow Sandoz to supply its high-quality, affordable medicines to independently owned and operated rural stores, which are the only healthcare providers in the rural communities of the country

Journey of Chronic Myeloid Leukemia (CML)

Wed, 29 Aug 2012 09:30:00 +0100

"Journey of Chronic Myeloid Leukemia" is the story of a fatal cancer that has been transformed into a chronic condition. CML is now considered the model for targeted therapy in hematology and oncology, as successful treatment has provided hope and inspiration for a number of other diseases.

Swiss Graduate Barometer 2012 – Handelszeitung

Tue, 28 Aug 2012 17:30:00 +0100

Novartis ranked most popular employer in healthcare by Swiss students in Swiss Graduate Barometer

Paul L. Herrling, Ph.D., explains the Glivec patent case in India

Wed, 22 Aug 2012 09:30:00 +0200

This week, the Supreme Court in India will hear arguments over whether the government had the right to deny a patent to Novartis for its Gleevec cancer medication. The case has focused attention on the contentious interplay between intellectual property rights and access to medicines by the economically disadvantaged. Novartis wants a patent based on a new form of its drug, which would offer a 20-year extension.

A look at the past decade in GIST: Chapter 5

Wed, 25 Jul 2012 11:30:00 +0200

Chapter 5 of the six chapter video series highlighting the significant medical advances throughout the past decade in the treatment of gastrointestinal stromal tumors. GIST is a rare and life-threatening cancer of the gastrointestinal tract.

Announcing second quarter performance

Thu, 19 Jul 2012 08:00:00 +0200

This three-minute video features Joe Jimenez reporting the Novartis results for the second quarter of 2012. He reviews the performance, highlights progress in innovation, and summarizes productivity and remediation of quality issues.

Novartis announces its second quarter 2012 results

Thu, 19 Jul 2012 07:10:00 +0200

Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook.

2012 European Graduate Barometer

Wed, 18 Jul 2012 11:30:00 +0200

Novartis enters the list of the 50 preferred employers among European Engineering/IT students.

Transparency in corporate reporting: Assessing the world's largest companies

Tue, 17 Jul 2012 14:30:00 +0200

Novartis named the most transparent large healthcare company by Transparency International.

Malaria experts join forces with Novartis to empower local communities to tackle malaria in Africa

Tue, 03 Jul 2012 15:30:00 +0200

The Novartis Malaria Initiative is convening global experts from education, government, community health and economics to share best practices and empower local African communities to deliver sustainable malaria healthcare. Roll Back Malaria, the World Health Organization, World Bank and the African Leaders Malaria Alliance are highlighting the urgent need to ensure malaria remains a priority in the current economic climate.

2012 Ethical Corporation Awards

Thu, 28 Jun 2012 10:30:00 +0200

Novartis wins Ethical Corporation Award for Best Corporate/NGO Partnership for SMS for Life

Novartis CEO Jimenez: Improving health will help Africa grow at world's fastest rate in coming decade

Wed, 27 Jun 2012 17:30:00 +0200

Novartis ranks No. 1 employer in Switzerland for students in Natural Science by Swiss business magazine Bilanz and Universum

Mon, 25 Jun 2012 15:30:00 +0200

The results of the Swiss Student Survey reveal how students perceive organizations as employers in Switzerland.

Healthcare in Africa

Mon, 25 Jun 2012 12:30:00 +0200

Think you know Africa? Take another look. New healthcare problems are on the rise, though old issues still exist. How can we improve healthcare in Africa?

Chairman Daniel Vasella, M.D.: spending more doesn't always lead to better care

Mon, 25 Jun 2012 11:30:00 +0200

Growing demand and the cost of health care are stretching the budgets not just in Massachusetts, but all over the world. Governments everywhere are faced with a stark choice: leave the health care system as it is and face rising taxes and declining quality of care, or start to do things differently.

Building the next generation of scientists

Mon, 25 Jun 2012 11:30:00 +0200

Novartis works to expand scientific and clinical capability in Africa and emerging countries. The result is mutually beneficial: Novartis gains insight into diseases in these areas, and the scientists gain connections and learn about Novartis research activities.

Africa's double burden

Fri, 22 Jun 2012 17:30:00 +0200

In the past, fast-spreading diseases were the continent's greatest threat—malaria, tuberculosis, HIV, measles, diarrhea, polio and other communicable diseases. These problems remain real and serious. But today, Africa's future may depend even more on battling chronic diseases that aren't spread between people, such as cancer, diabetes and cardiovascular disease.

Africa's growing need for medical expertise

Fri, 22 Jun 2012 17:30:00 +0200

Africa is on the rise. The evidence is everywhere. In a 2011 report, the World Bank declared that "Africa could be on the brink of an economic take-off." The World Health Organization (WHO) 2011 African Regional Health Report revealed that Africa has made significant progress in the battle against many communicable diseases, including river blindness, malaria, leprosy and measles, among others.

The two Africas

Fri, 22 Jun 2012 17:30:00 +0200

In May 2000, The Economist ran a cover story on Africa under the headline, "The Hopeless Continent." The article detailed violence and disease ravaging the region -- the cover pictured a fighter with a weapon on his shoulder framed by an African map.

The fight against malaria: over 500 million antimalarial treatments delivered

Thu, 14 Jun 2012 11:30:00 +0200

Novartis has reached a significant milestone: 500 million Novartis antimalarial treatments have been delivered - without profit - to endemic countries in Africa since 2001.

Novartis Foundation for Sustainable Development hosts dialogue on achieving zero transmission of leprosy

Wed, 13 Jun 2012 13:30:00 +0200

The Novartis Foundation for Sustainable Development, together with CIOMAL Foundation convened an experts' meeting on innovative solutions to tackling the last mile of leprosy on 31 May 2012 in Geneva.

Novartis Malaria Initiative SMS for Life program wins Computerworld's 21st Century Achievement Awards

Wed, 06 Jun 2012 14:30:00 +0200

SMS for Life has been selected as the Laureate in the Innovation IT category of the 2012 Computerworld Honors Program. This award recognizes organizations that promote and advance the public welfare, benefit society and change the world for the better through a visionary application of IT.

Bilanz magazine Sustainability Ranking 2012

Tue, 05 Jun 2012 10:30:00 +0200

Novartis again ranked as a top sustainability performer.

The Scientist's Best Places to Work: Industry 2012

Mon, 04 Jun 2012 10:30:00 +0200

Novartis again among top 20 companies globally climbing one spot to No. 17.

Novartis is again second in PharmExec's 2012 ranking of the top 50 pharma companies based on Rx sales.

Wed, 23 May 2012 11:30:00 +0200

This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.

Be Healthy: the first company-wide health and well-being initiative at Novartis

Wed, 09 May 2012 11:30:00 +0200

As a healthcare company, Novartis recognizes that employees are an integral part of the company's success and a healthy workforce underpins business growth. The "Be Healthy" initiative, first introduced in 2011, has expanded to include all Novartis associates across 140 countries.

FT Bowen Craggs Index 2012

Mon, 07 May 2012 17:30:00 +0200

Bowen Craggs ranks Novartis No.8 in its 6th annual index of corporate web effectiveness, making it the second healthcare company on the list.

Novartis named #3 Most Valuable Swiss Brand 2012

Fri, 04 May 2012 10:30:00 +0200

Novartis named #3 Most Valuable Swiss Brand 2012 by Interbrand/Bilanz with a brand value of CHF 6.8 billion.

Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US

Thu, 03 May 2012 10:30:00 +0200

Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction.

Q1 2012 media release

Tue, 24 Apr 2012 10:30:00 +0200

Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges

Leo and Kya, friends against malaria, are telling the story about malaria in Africa

Thu, 19 Apr 2012 11:00:00 +0200

Leo and Kya are very good friends. Kya is from Africa, and one day, she was telling Leo about malaria in Africa ... Help raise awareness, educate your children and join the fight against malaria!

The need for progress: what if?

Fri, 13 Apr 2012 13:00:00 +0200

What if questions have always driven human progress. With today's health challenges, medical progress is more important than ever.

Novartis commitment to the research and treatment of rare diseases highlighted in Medical Marketing & Media

Wed, 04 Apr 2012 18:45:00 +0200

A target of 300 endocrinologists seems pretty specific. And small. After all, health headlines often focus on broad issues, like the 78 million obese adults or the 26 million Americans with diabetes.

Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines

Wed, 28 Mar 2012 18:00:00 +0200

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today[1], may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

Brand-Finance's Top 500 most valuable global brand 2012

Mon, 19 Mar 2012 17:00:00 +0100

Novartis ranked as one of the "Global 500 most valuable brands" and one of the top brands in the pharmaceutical/healthcare sector.

Novartis CEO Joseph Jimenez receives "CEO in Action" award and discusses diversity in Profiles in Diversity Journal

Wed, 14 Mar 2012 18:00:00 +0100

Mr. Jimenez was recognized for his commitment and engagement in Novartis Diversity & Inclusion initiatives.

Fortune's World's Most Admired Companies 2012

Fri, 02 Mar 2012 18:45:00 +0100

Novartis again ranked top pharmaceutical company in Fortune's World's Most Admired Companies 2012

Novartis works for patients with rare diseases

Fri, 24 Feb 2012 18:45:00 +0100

From pioneering Novartis medicines used by patients worldwide to treat rare forms of cancer to potential medical breakthroughs now undergoing clinical testing, our commitment to rare diseases has never been stronger. Underscoring that commitment, Novartis headquarters in Basel, Switzerland, will host the RE(ACT) Congress, the first international congress on research of rare and orphan diseases, from February 29 to March 2.

Watch how Novartis and Medicines for Malaria Venture worked together to develop a child-friendly antimalarial

Wed, 22 Feb 2012 17:00:00 +0100

One child dies from malaria every minute, so a child-friendly medicine against the disease is critical. Novartis and MMV began working together in 2003 to develop the first pediatric formulation for an artemisinin combination therapy (ACT) against malaria.

Delivery of child-friendly antimalarial hits the 100 million mark

Wed, 22 Feb 2012 14:00:00 +0100

In 2009, Novartis and MMV launched the first child friendly artemisinin-combination therapy (ACT), meeting the calls from UNICEF and the WHO for age-appropriate medicines. Three years after launch, deliveries of this child-friendly antimalarial hit the 100 million mark.

Treating leprosy, caring for patients

Tue, 14 Feb 2012 16:00:00 +0100

Novartis CEO Joseph Jimenez explains the company's commitment to fighting leprosy and why we need continued focus to eliminate the disease.

University teams tap mobile phones and social networks to fight noncommunicable diseases

Fri, 10 Feb 2012 12:00:00 +0100

New solutions developed by university teams could help manage the growing global problem of noncommunicable diseases (NCDs) such as asthma, diabetes, stroke and cancer. These innovations were part of the NCD Challenge, sponsored by IBM and Novartis.

Novartis continues fight to help end leprosy

Mon, 30 Jan 2012 12:00:00 +0100

Novartis announced today that it will extend its collaboration with the World Health Organization and others to end leprosy.

Novartis delivers strong underlying financial performance in 2011

Wed, 25 Jan 2012 07:00:00 +0100

Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011.

"SMS for Life" is expanding

Tue, 17 Jan 2012 15:30:00 +0100

"SMS for Life" uses SMS and web based technology to expand access to medicines in the most remote areas of the world. After Tanzania and Ghana, "SMS for Life" is being implemented in Kenya and beyond antimalarials, RDTs, bed nets, antibiotics or patient surveillance data can now also be monitored.

Becoming Christopher a fictional video trailer about living with Cycstic Fibrosis

Mon, 16 Jan 2012 11:00:00 +0100

The Becoming Christopher video trailer tells the fictional story of Christopher Morgan, a 22-year-old fictional character with cystic fibrosis, on his journey to adulthood.

Pioneering an innovative social business model to fight malaria

Thu, 22 Dec 2011 09:00:00 +0100

Malaria remains a complex and multi-faceted problem in sub-Saharan Africa. Professor Rodriguez, Harvard University, Professor Coll-Seck, Exec. Dir. Roll Back Malaria, and Agnes Akoth, head nurse, Kombewa Clinic in Kenya, look more closely at the impact of malaria in Africa, and examine the journey Novartis undertook to apply innovation and make global access possible for patients of all backgrounds, in all locations.

New media: drivers of democratization and development?

Mon, 19 Dec 2011 18:00:00 +0100

In December, 2011 in Basel, the 16th annual symposium of the Novartis Foundation for Sustainable Development (NFSD) discussed the potential of Information and Communication Technologies (ICT) for democratization and development.

Novartis Foundation symposium debates new media

Mon, 19 Dec 2011 15:30:00 +0100

The rise of new media has sparked a real knowledge revolution – this is the conclusion of the annual symposium of the Novartis Foundation for Sustainable Development (NFSD), attended by around 500 participants on 2 December 2011, on the topic of "New media: drivers of democratization and development?"

Novartis Foundation symposium looks at impact of Information and Communication Technology on democratization and development

Fri, 02 Dec 2011 15:00:00 +0100

Experts analyze how e-health applications improve access to quality healthcare and help contribute to achieving the health-related Millennium Development Goals. The symposium discusses the role of social media platforms in the Arab Spring and the impact of mobile phone penetration into the African continent. The annual Novartis Foundation symposium provides an important platform for dialogue on development policy issues.

Molecular pathways: The future of research at the Novartis Institutes for BioMedical Research

Wed, 30 Nov 2011 12:00:00 +0100

See how scientists at the Novartis Institutes for BioMedical Research, have embraced a new way of thinking about disease that looks at the role of molecular pathways.

Fighting malaria

Thu, 17 Nov 2011 20:00:00 +0100

Novartis and collaborators discover new class of antimalarial compounds with potential to both prevent and treat malaria infections.

The Novartis Malaria Initiative: lessons from a dramatic decade

Thu, 17 Nov 2011 20:00:00 +0100

In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria - without profit - for use by public health systems in developing countries.

2011 Scrip Awards

Thu, 10 Nov 2011 16:00:00 +0200

Novartis received three 2011 Scrip Awards: Pharma Company of the Year, Best New Drug and Executive of the Year.

Newsweek's 2011 Green Rankings

Tue, 8 Nov 2011 18:00:00 +0200

Novartis ranks no. 34 on the global list of Newsweek's 2011 "Green Rankings." For the first time this year, Newsweek expanded its "Green Rankings" to analyze the green score of the 100 biggest companies worldwide.

Justmeans' 2011 ranking

Tue, 8 Nov 2011 17:30:00 +0200

Novartis ranks #6 in the "Sustainable Performance Leaders in Pharmaceuticals" list released by JustMeans.

Fortune's 2011 "Top Companies for Leaders"

Tue, 8 Nov 2011 15:30:00 +0200

Novartis ranks #25 in Fortune's 2011 "Global Top Companies for Leaders" list for the quality of its leadership practices.

MedAdNews 2011 "Most Admired Pharmaceutical Company"

Fri, 28 Oct 2011 16:15:00 +0200

Novartis is named "Most Admired Pharmaceutical Company" by MedAdNews.

Novartis "SMS for Life" program wins 2011 WSJ Technology Innovation Award in Health-Care IT category.

Tue, 18 Oct 2011 18:00:00 +0200

These global awards recognize game-changing innovations that break with conventional ideas or processes, go beyond marginal improvements and have a wide impact in their field. Led by Novartis, in partnership with IBM, Vodafone, the Ministry of Health in Tanzania, and under the umbrella of the Roll Back Malaria Partnership, SMS for Life harnesses everyday technology to improve access to essential malaria medicines in rural areas. Since rolling out nationally across Tanzania in April 2011, the program has expanded to Ghana and Kenya.

Novartis is the most valuable corporate healthcare brand in Europe and third worldwide.

Mon, 17 Oct 2011 18:00:00 +0200

Novartis was ranked the most valuable healthcare brand in Europe (no. 20) and the third most valuable worldwide (no. 54) in the annual "eurobrand" rankings published by the European Brand Institute, Europe's leading research institute for intangible assets.

MedAdNews 2011 "Top 50 Pharma Companies"

Fri, 7 Oct 2011 13:00:00 +0200

Novartis is named the "Pharmaceutical Company of the Year" by MedAdNews.

Be Healthy is an internal initiative for the benefit of Novartis associates.

Mon, 19 Sep 2011 16:00:00 +0200

Joseph Jimenez, CEO of Novartis, talks about how Novartis Group Company associates across 32 countries are participating in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011.

First Novartis company-wide health and well-being initiative

Mon, 19 Sep 2011 07:20:00 +0200

Be Healthy aims to help Novartis Group Company associates around the world embrace healthy lifestyles by providing opportunities for them to take control of their personal health and help prevent future health issues.

Novartis associates participate in first company-wide health and well-being initiative

Mon, 19 Sep 2011 07:15:00 +0200

Novartis Group Company associates across 32 countries will participate in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011. During the week, Novartis Group sites are offering many opportunities to help associates take control of their personal health. This includes providing information, activities and tips to promote health and help prevent future health issues.

Novartis increases growth potential through integration of Alcon

Tue, 13 Sep 2011 12:00:00 +0200

Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division. The company's diversified healthcare portfolio across high growth segments in healthcare as well as geographic distribution provides Novartis with strength and advantages to benefit from current trends in healthcare as well as protection from macroeconomic effects.

Novartis BioCamp 2011

Fri, 2 Sep 2011 10:30:00 +0200

Today's best young talent will soon be changing the world. Novartis International Biotechnology Leadership Camp (BioCamp) offers top university students the opportunity to apply their bright minds to the trends and challenges of the biotechnology and healthcare industry and think like entrepreneurs. This year's BioCamp welcomed 60 participants to Novartis Headquarters in Basel, Switzerland, from August 29 to August 31, 2011.

Fostering innovation among diverse young talent

Thu, 1 Sep 2011 10:00:00 +0200

Future science and business leaders gathered at Novartis as some of the world's most talented students met and exchanged ideas at the International BioCamp.

Novartis International BioCamp spotlights how diversity spurs innovation across the company and inspires future science leaders

Thu, 01 Sep 2011 17:10:00 +0200

Today, Novartis opened its eighth annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 60 selected students from leading international universities in 24 countries and territories. This year, Novartis highlighted the growing role of diversity in Group Companies worldwide to drive innovation in all aspects of the company including scientific research and development.

BioCamp - Novartis International Biotechnology Leadership Camp

Mon, 29 Aug 2011 07:30:00 +0200

Future science and business leaders gathered at Novartis as some of the world's most talented students met and exchanged ideas at the International Biotechnology Leadership Camp (BioCamp).

What is the prognosis of myelofibrosis (MF)?

Wed, 13 Jul 2011 17:40:00 +0200

Dr. David Ross and Dr. Claire Harrison address the prognosis of myelofibrosis.

How are myeloproliferative neoplasms (MPNs) diagnosed?

Thu, 07 Jul 2011 14:30:00 +0200

Dr. Alessandro Vannucchi explains how myeloproliferative neoplasms (MPNs) are diagnosed.

What are myeloproliferative neoplasms (MPNs)?

Thu, 07 Jul 2011 14:30:00 +0200

Dr. Claire Harrison explains myeloproliferative neoplasms (MPNs).

Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia

Thu, 16 Jun 2011 17:30:00 +0200

Novartis today held a groundbreaking ceremony to announce the start of construction of a pharmaceutical manufacturing plant in St. Petersburg, Russia. The construction of this facility represents the most significant Novartis investment in Russia to date. This facility will further expand the company's capabilities to produce and deliver both innovative pharmaceuticals and high-quality generics to Russian patients.

Living with multiple myeloma

Thu, 16 Jun 2011 13:05:00 +0200

A woman diagnosed with multiple myeloma that has seriously impacted her bone health, joins a pet therapy program as a way to give back to others.

Gastrointestinal Stromal Tumors (GIST): A rare, life-threatening cancer

Mon, 06 Jun 2011 15:00:00 +0200

Gastrointestinal Stromal Tumors (GIST) are a rare, life-threatening form of cancer. Listen to four patient stories about living with the disease.

2011 GBC Business Action on Health Awards

Mon, 23 May 2011 17:30:00 +0200

2011 GBC Business Action on Health Awards 'SMS for Life', a Novartis Malaria Initiative program, ranked #1 in Technology for Health category.

Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly

Thu, 19 May 2011 17:30:00 +0200

Novartis welcomes the decision to endorse the Pandemic Influenza Preparedness Framework (PIP Framework) at the Sixty-fourth World Health Assembly. The PIP Framework sets out the roles and commitments of different stakeholders, including the World Health Organization (WHO) and vaccine manufacturers, in pandemic preparedness.

Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data

Wed, 18 May 2011 07:00:00 +0200

Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc.

The Scientist's Best Places to Work in Industry 2011

Thu, 05 May 2011 11:35:00 +0200

Novartis ranks #6 among large companies for The Scientist Best Places to Work in Industry 2011.

Animals & Research: Think how far we've come

Tue, 03 May 2011 16:20:00 +0200

Animal research is an important part of the research process when developing new treatments and medicines for patients. No one likes the idea, but as science has not evolved enough to make animal research unnecessary -- for now, this is how we make sure medicines are safe.

The Novartis Malaria Initiative: lessons from a dramatic decade

Fri, 22 Apr 2011 10:00:00 +0200

In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria – without profit - for use by public health systems in developing countries.

Fighting Malaria in Africa

Wed, 20 Apr 2011 10:00:00 +0200

Two African mothers struggle to find treatment for their daughters who are battling Malaria. Learn about the severity of the endemic and the complexity surrounding Malaria treatment and diagnosis in Africa.

Novartis makes strong start for the year

Tue, 19 Apr 2011 07:00:00 +0200

Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Contributions from all businesses led to a good start in 2011, as we achieved 14% growth in the first quarter. We maintained our innovation momentum with new approvals for our multiple sclerosis treatment Gilenya and our eye care treatment Lucentis in the EU. Additionally, promising results of numerous clinical trials, including a Phase III study involving JAK inhibitor INC424, again showed the success of our novel approach to R&D. In April, we completed our merger with Alcon, the leading eye care business in the world, creating the second-largest business in the Novartis portfolio."

Stronger together: Novartis and Alcon creating the global leader in eye care

Fri, 08 Apr 2011 17:00:00 +0200

Together, Novartis and Alcon will hold competitive positions in highly complementary product areas and create an even stronger global leader in the dynamic eye care sector.

Novartis CEO Joseph Jimenez discusses Alcon merger

Fri, 08 Apr 2011 17:00:00 +0200

We have a great opportunity to redefine and shape the eye care industry, with the ultimate goal of preventing blindness and treating diseases and disorders of the eye.

Kevin Buehler, Division Head, Alcon, discusses merger with Novartis

Fri, 08 Apr 2011 17:00:00 +0200

Completion of the merger with Novartis strengthens Alcon's position as the global leader in eye care and increases the breadth of our eye care portfolio.

International BioCamp 2011

Fri, 01 Apr 2011 17:00:00 +0200

International BioCamp application process for students has begun. Apply today and get qualified for nomination to attend the 3 day event.

VetDogs

Fri, 25 Mar 2011 17:00:00 +0100

VetDogs: enriching life for disabled veterans. Watch the video on YouTube

Japan update

Thu, 17 Mar 2011 17:00:00 +0100

Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquakevictims

Diagnosing a rare autoinflammatory disease

Tue, 15 Mar 2011 17:00:00 +0100

Diagnosing a rare autoinflammatory disease: CAPS. Watch the video on YouTube

Novartis continues fight to end leprosy

Mon, 11 Oct 2010 19:55:00 +0200

Novartis and the World Health Organization (WHO) announced October 11 that they will extend their collaboration to end leprosy.

New medicines for neglected diseases

Thu, 05 Aug 2010 21:15:00 +0200

Novartis is pioneering medicines for neglected diseases, with institutes focusing solely on diseases for which research was virtually non-existent.

Funding future research

Thu, 05 Aug 2010 21:15:00 +0200

Novartis is leading industry efforts to fill a multi-billion-dollar gap in neglected disease R&D funding.

Novartis & Citizenship

Wed, 23 Jun 2010 14:45:00 +0200

See Novartis Chairman Daniel Vasella, M.D., discuss the values and principles of the United Nations Global Compact on its 10th anniversary.

Living the Global Compact

Wed, 23 Jun 2010 14:45:00 +0200

In a wide-ranging interview, Klaus Leisinger describes how Novartis embodies the principles of the United Nations Global Compact.

Environment & Energy

Wed, 23 Jun 2010 14:45:00 +0200

Keith Saveal, Head of Corporate Health, Safety and Environment & Business Continuity, recounts the evolution of the new UN Environmental Stewardship Strategy.

CIBA VISION creates mobile 'app' to train healthcare providers

Fri, 21 May 2010 19:00:00 +0200

Eye care professionals are benefiting from an innovative new iPhone® application offering 'anytime, anywhere' access to high-quality educational resources.

April 25 is World Malaria Day

Fri, 23 Apr 2010 09:55:00 +0200

On World Malaria Day, April 25, the international community highlights the campaign to provide effective control of this deadly disease.

Seeking a clearer view of multiple sclerosis

Thu, 22 Apr 2010 14:07:00 +0200

People with multiple sclerosis (MS) face devastating uncertainty, not knowing how the disease will progress or disrupt their daily lives. But scientists are developing new diagnostic tools to aid treatment and ease the unpredictability for patients.

Innovating beyond the Vaccine: VaxTrak puts value in the hands of patients and families

Thu, 18 Feb 2010 19:15:00 +0100

Novartis Vaccines and Diagnostics (NV&D) has developed a way to help parents, families and vaccine consumers track vaccinations using the iPhone ®.

New products rejuvenate our pharmaceutical portfolio

Tue, 26 Jan 2010 07:05:00 +0100

Just as new medicines are improving the lives of patients fighting serious diseases, success in innovation is rejuvenating the portfolio of Novartis. Recently launched products grew to 16% of net sales for the Pharmaceuticals Division in 2009.

Novartis joins urgent relief efforts for victims of earthquake in Haiti

Fri, 22 Jan 2010 11:15:00 +0100

Novartis joins urgent relief efforts for victims of earthquake in Haiti offering aid in the form of financial support to relief organizations and donations of essential medicines.

Legal team helps navigate through economic crisis

Thu, 14 Jan 2010 21:15:00 +0100

In times of global financial uncertainty, the Novartis legal team takes an innovative approach – serving as both a protective guardian and a proactive partner to the business.

BioCamp prompts young scholars to look at biotech

Wed, 25 Nov 2009 17:25:00 +0100

Today's best young minds will soon be changing the world. Novartis has created a unique global initiative encouraging top students to apply their intellects in the biotechnology industry – and to think like entrepreneurs.

Good governance in economic crisis

Wed, 25 Nov 2009 17:25:00 +0100

A board of directors can restore confidence in the wake of a financial meltdown. On a panel at Yale University, Novartis General Counsel Thomas Werlen helps outline the qualities of a successful board.

New treatment option for frequent heartburn

Thu, 12 Nov 2009 08:55:00 +0100

More than 50 million American adults suffer from frequent heartburn. Painful symptoms can disrupt their lives. Now Novartis Consumer Health offers Prevacid®24HR, a new way to treat frequent heartburn over-the-counter.

Novartis committed to new therapies for multiple sclerosis (MS) community

Mon, 19 Oct 2009 13:00:00 +0200

Recent advances in science are enabling new treatments with greater efficacy and more convenient delivery. Novartis is investing significant resources to deliver these treatments to patients with MS.

Easing the pain of cats and dogs

Thu, 01 Oct 2009 16:25:00 +0200

An innovative new Novartis product brings fast, effective relief of pain and inflammation for pets. Onsior®, launched in Europe, is the first medication of its class for cats and dogs. The range of dosing options offer convenience for veterinarians and pet owners.

Novartis marks 20-year commitment in the fight against leprosy

Tue, 08 Sep 2009 16:50:00 +0200

The once-dreaded disease leprosy is on the brink of elimination, but the fight goes on. Novartis commemorates 20 years of helping deliver free care, drugs and rehabilitation in India.

Novartis addresses climate change

Wed, 22 Jul 2009 11:15:00 +0200

World leaders are focused on climate change and Novartis is, too. Our cutting-edge energy efficiency strategy is a driving long-term success for the environment and for our business.

Life-saving research rewarded

Wed, 20 May 2009 14:00:00 +0200

Scientists who developed Novartis Coartem® and Glivec® receive 2009 "European Inventor of the Year" awards.

Novartis in the fight against malaria

Fri, 24 Apr 2009 00:00:00 +0200

April 25 is World Malaria Day, an opportunity to reflect on the progress made in finding sustainable solutions for malaria.

A Revolutionary Collaboration

Tue, 31 Mar 2009 00:00:00 +0200

With declining efficacy and resistance to existing sheep worm treatments on the rise, Novartis Animal Health worked together with sheep farmers and veterinarians to develop an unparalleled new treatment.

Novartis in the fight against tuberculosis

Thu, 19 Mar 2009 00:00:00 +0100

As World TB Day on March 24 raises global awareness, Novartis remains a committed partner in the struggle.

A rare opportunity

Fri, 27 Feb 2009 00:00:00 +0100

The challenges of developing products in rare diseases are many - but no obstacle for Novartis Development teams.

Meeting healthcare needs in emerging markets

Wed, 04 Feb 2009 00:00:00 +0100

Novartis is working to expand its offering in emerging markets including Brazil, Russia, India and China.